A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Phase 1
Active, not recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Gasherbrum Bio, Inc
- Target Recruit Count
- 70
- Registration Number
- NCT06139055
- Locations
- ๐บ๐ธ
ERG Clinical (Clinical Pharmacology of Miami - CPMI), Miami, Florida, United States
๐บ๐ธParexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
๐บ๐ธSyneos Miami Site, Miami, Florida, United States
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Gasherbrum Bio, Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05893043
- Locations
- ๐บ๐ธ
ACT, Anaheim, California, United States
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Type2 Diabetes MellitusOverweight or Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Gasherbrum Bio, Inc
- Target Recruit Count
- 142
- Registration Number
- NCT05762471
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, Anaheim, California, United States
๐บ๐ธProSciento, Inc, Chula Vista, California, United States
๐บ๐ธProgressive Medical Research, Port Orange, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath